SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 9, 2001
-------------
SALIX PHARMACEUTICALS, LTD.
----------------------------------------------------------
(Exact name of registrant as specified in its charter)
British Virgin Islands
- -------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
- ---------------------------------- -------------------------------
(Commission file Number) (IRS Employer ID Number)
3801 Wake Forest Road, Raleigh, North Carolina 27609
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 862-1000
----------------------------
Item 5. Other Events.
On April 9, 2001, Salix Pharmaceuticals, Ltd. announced that it would be
making a presentation on April 10, 2001 at an investor conference sponsored by
The Robinson-Humphrey Company.
A copy of this press release is attached as an exhibit.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated April 9, 2001
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: April 9, 2001 By: /s/ Adam C. Derbyshire
-------------------------------------
Adam C. Derbyshire
Vice President and Chief Financial
Officer